Uhe I, Hagen ME, Ris F, Meyer J, Toso C, Douissard J. Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A systematic review. World J Gastrointest Oncol 2021; 13(11): 1799-1812 [PMID: PMC8603462 DOI: 10.4251/wjgo.v13.i11.1799]
Corresponding Author of This Article
Jonathan Douissard, MD, Surgeon, Abdominal Surgery Division, Geneva University Hospitals, Rue Gabrielle Perret Gentil 4, Geneva 1211, Switzerland. jonathan.douissard@hcuge.ch
Research Domain of This Article
Oncology
Article-Type of This Article
Systematic Reviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1799-1812 Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1799
Cell-free DNA liquid biopsy for early detection of gastrointestinal cancers: A systematic review
Isabelle Uhe, Monika Elisabeth Hagen, Frédéric Ris, Jeremy Meyer, Christian Toso, Jonathan Douissard
Isabelle Uhe, Monika Elisabeth Hagen, Frédéric Ris, Jeremy Meyer, Christian Toso, Jonathan Douissard, Abdominal Surgery Division, Geneva University Hospitals, Geneva 1211, Switzerland
Author contributions: Uhe I and Douissard J designed the review, performed studies selection, data analysis, and wrote the manuscript. All authors performed critical revision of the manuscript and approved its final version.
Conflict-of-interest statement: Dr. Uhe and Dr. Meyer have nothing to disclose. Dr. Hagen reports grants from Intuitive Surgical Inc., grants, personal fees and non-financial support from Johnson&Johnson Inc., personal fees and non-financial support from Verb Surgical Inc., personal fees from Verily, non-financial support from Quantgene Inc., personal fees from I2X, outside the submitted work. Pr. Ris reports personal fees and non-financial support from Stryker Inc., grants from Quantgene Inc., outside the submitted work. Pr. Toso reports grants, personal fees, and non-financial support from Johnson&Johnson Inc., outside the submitted work. Dr. Douissard reports grants and non-financial support from Intuitive Surgical Inc., personal fees from Verb Surgical Inc., grants, personal fees, and non-financial support from Johnson&Johnson Inc., outside the submitted work.
PRISMA 2009 Checklist statement: This systematic review of the literature was performed following the PRISMA 2009 guidelines.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jonathan Douissard, MD, Surgeon, Abdominal Surgery Division, Geneva University Hospitals, Rue Gabrielle Perret Gentil 4, Geneva 1211, Switzerland. jonathan.douissard@hcuge.ch
Received: March 1, 2021 Peer-review started: March 1, 2021 First decision: June 23, 2021 Revised: July 6, 2021 Accepted: September 7, 2021 Article in press: September 7, 2021 Published online: November 15, 2021 Processing time: 255 Days and 16.8 Hours
ARTICLE HIGHLIGHTS
Research background
Liquid biopsy cell-free DNA (cfDNA) represents a promising non-invasive method for detecting various gastrointestinal cancers at an early stage of development.
Research motivation
Various and recent literature is available on this topic, with exponentially growing interest.
Research objectives
To review the current state of development of cfDNA liquid biopsy in the field of gastrointestinal cancer early detection.
Research methods
A systematic review of the literature according to the PRISMA guidelines.
Research results
The current literature suggests a high-performance profile for this technology and the potential to improve the global course of gastrointestinal cancers currently diagnosed at an advanced stage, such as pancreatic cancer.
Research conclusions
cfDNA liquid biopsy showed high potential in the diagnosis of early gastrointestinal cancers and simultaneous screening of multiple cancer types.
Research perspectives
Further trials in clinically relevant settings are required to determine the exact place of this technology in future diagnosis strategies.
